title: [Immunoglobulins in PID, SID and neurological autoimmune disease].
abstract: Human immunoglobulins (IG, mostly IgG) are used as replacement therapy in                     patients with inherited primary immunodeficiencies, and in patients with                     secondary immuno-deficiencies often observed in multiple myeloma or chronic                     lymphocytic leukemia. Ig are also approved as immunomodulatory therapy in                     neurological autoimmune diseases (NAID) such as Guillain-Barré syndrome, chronic                     inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy                     (MMN). 16 different Ig preparations for intravenous and subcutaneous use are at                     the moment available in Germany. The SIGNS study (Assessment of                         immunoglobulins in a long-term non-interventional                         study) investigates the clinical use of these drugs under clinical                     practice conditions. In this non-interventional prospective open-label cohort                     study, 550 patients with new or maintenance Ig therapy are observed with respect                     to drug utilization, effectiveness, (i. e. number of infections in PID and SID,                     functionality in NAID), tolerability, quality of life and costs in approximately                     50 sites throughout Germany (neurologists, pediatricians, oncologists, other)                     for at least two years. This largest study of its kind is expected to contribute                     to optimization of Ig therapy in the postmarketing setting.
authors.affiliation: Fachbereich Pädiatrische Rheumatologie, Immunologie und Infektiologie am Klinikum St. Georg gGmbH Leipzig.
authors.forename: M
authors.initials: M
authors.lastname: Borte
authors.forename: U
authors.initials: U
authors.lastname: Baumann
authors.forename: D
authors.initials: D
authors.lastname: Pittrow
authors.forename: M
authors.initials: M
authors.lastname: Hensel
authors.forename: M
authors.initials: M
authors.lastname: Fasshauer
authors.forename: D
authors.initials: D
authors.lastname: Huscher
authors.forename: M
authors.initials: M
authors.lastname: Reiser
authors.forename: M
authors.initials: M
authors.lastname: Stangel
authors.forename: R
authors.initials: R
authors.lastname: Gold
authors.forename: W
authors.initials: W
authors.lastname: Kirch
mesh_terms: D020274:Autoimmune Diseases of the Nervous System / Q000188:drug therapy*; D015331:Cohort Studies; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use*; D007153:Immunologic Deficiency Syndromes / Q000188:drug therapy*; D007155:Immunologic Factors / Q000627:therapeutic use*
chemical_list: D007136:Immunoglobulins; D007155:Immunologic Factors